VerImmune is at the forefront of innovation, dedicated to the development of a groundbreaking first-in-class cancer immunotherapy called Anti-tumor Immune Redirection (AIR). This unique strategy leverages a proprietary virus-inspired particle (ViP) technology platform to redirect pre-existing pathogenic or childhood vaccine immune memory toward tumors. VerImmune's lead immuno-oncology product candidate, VERI-101, utilizes the ViP platform to harnesses the cellular immune memory responses from prior cytomegalovirus (CMV) infection to fight cancer. Such a mechanism of action not only differentiates VerImmune within the competitive Immuno-Oncology market but also has the potential to redefine the treatment paradigm, as a stand-alone product or in combination with other immunotherapies, for patients with untreatable cancers or resistance to existing therapies.